FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

9 results

ahzantive
(aflibercept-mrbb)
Valorum Biologics Inc
Usage: AHZANTIVE is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
beovu
(brolucizumab)
Novartis Pharmaceuticals Corporation
Usage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
cimerli
(ranibizumab-eqrn)
Coherus BioSciences Inc
Usage: CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
eylea
(aflibercept)
Regeneron Pharmaceuticals, Inc.
Usage: EYLEA is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity.
eylea hd
(aflibercept)
Regeneron Pharmaceuticals, Inc
Usage: EYLEA HD is indicated for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
iluvien
(fluocinolone acetonide)
Alimera Sciences, Inc.
Usage: ILUVIEN® is indicated for the treatment of diabetic macular edema in patients previously treated with corticosteroids without significant intraocular pressure rise, and for chronic non-infectious uveitis affecting the posterior segment of the eye.
lucentis
(RANIBIZUMAB)
Genentech, Inc.
Usage: LUCENTIS is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
susvimo
(Ranibizumab)
Genentech, Inc.
Usage: SUSVIMO (ranibizumab injection) is indicated for treating Neovascular (wet) Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.
vabysmo
(Faricimab)
Genentech, Inc.
Usage: VABYSMO is indicated for treating patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It acts as a VEGF and angiopoietin 2 (Ang-2) inhibitor.

Medications for Macular Edema Due To Diabetes Mellitus

ahzantive

beovu

cimerli

eylea

eylea hd

iluvien

lucentis

susvimo

vabysmo